Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)
NCT04375800
Recruiting
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The first primary objective is to evaluate the steady state pharmacokinetics (PK) of doravirine (DOR) \[MK-1439\] when given in combinat... Read More
Gender:
ALL
Ages:
Between 4 weeks and 11 years
Trial Updated:
07/10/2025
Locations: University of Colorado at Denver ( Site 0108), Aurora, Colorado +23 locations
Conditions: Human Immunodeficiency Virus (HIV) Infection
Register for Updates
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT05000294
Recruiting
Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite its demonstrated potential, immunotherapy is not currently thought to be an effective intervention in the treatment of several immunologically "cold" tumors such as prostate cancer, biliary tract cancers, soft tissue sarcomas, well-differentiated... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/10/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
Register for Updates
Arrhythmia Detection After MI
NCT05073419
Recruiting
Patients post acute myocardial infarction (AMI) have a high risk of mortality but the use of an implantable defibrillator in the early aftermath of an AMI has not been shown to improve patients' survival. The VEST trial recently demonstrated an improved overall survival in post AMI patients with the use of a wearable defibrillator. The same improvement was not demonstrated for the risk of sudden cardiac death. Monitoring patients after AMI using an implantable cardiac monitor (ICM) may document... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania
Conditions: Acute Myocardial Infarction
Register for Updates
Neurofeedback to Treat Depression
NCT05169346
Recruiting
This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD (60 in R61 phase and 80 in R33 Phase). This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamically modulate task stimuli (in a closed loop) based on this state.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/10/2025
Locations: Center for Neuromodulation in Depression and Stress, Philadelphia, Pennsylvania
Conditions: MDD
Register for Updates
Telehealth Parent-Implemented Intervention for Young Children With Autism Spectrum Disorder (ASD)
NCT05176808
Recruiting
The primary objective of this research study is to improve outcomes involving core social-communication symptoms for young children with ASD or social communication delays by increasing access to clinically validated early behavioral intervention through a telehealth parent coaching model. The investigators will test the hypothesis that telehealth-delivered Naturalistic Developmental Behavioral Intervention parent coaching (TC) is non-inferior to in-person coaching (IPC) for the treatment of cor... Read More
Gender:
ALL
Ages:
Between 18 months and 42 months
Trial Updated:
07/10/2025
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Autism Spectrum Disorder, Autistic Disorder, Active Autistic Disorder, Autism, Asperger Syndrome, PDD-NOS, Social Communication Delay, Mixed Expressive Receptive Language Disorder, Other Symbolic Dysfunctions
Register for Updates
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
NCT05183828
Recruiting
This stage IV trial examines how a mutation in HSD3B1 (1245C) gene affects treatment of stage I-III breast cancer. This trial may help researchers determine if mutations in HSD3B1 decreases the efficacy of aromatase inhibitor therapy such as letrozole. Letrozole may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma of No Special Type
Register for Updates
Enhancing Voluntary Motion in Broad Patient Populations With Modular Powered Orthoses
NCT05240014
Recruiting
The overall goal of this project is to develop modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. This project aims to establish feasibility of assisting different populations with these modular powered orthoses. The investigators hypothesize that assisting lower-limb musculature with modular powered orthoses will improve 1) lifting/lowering posture in able-bodied subjec... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/10/2025
Locations: Rehab Lab, University of Michigan, Ann Arbor, Michigan
Conditions: Lower-limb Orthoses, Frailty/Sarcopenia, Chronic Overuse Musculoskeletal Injuries
Register for Updates
Omalizumab Before Onset of Exacerbations
NCT05332067
Recruiting
OBOE is a prospective, pilot, parallel group RCT with the overall aim of examining the effect of a single dose of anti-IgE (omalizumab) vs. placebo administered at the onset of URIs in the fall season among highly exacerbation-prone, urban, and atopic youth aged 6-17 years with persistent asthma. OBOE will recruit and randomize participants over 3 years (3 annual cohorts of participants). Recruitment for each of the yearly cohorts of OBOE will begin in February. Each cohort will be followed for... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/10/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Asthma in Children, Atopy, Viral Upper Respiratory Infection
Register for Updates
Intracardiac Flow Assessment in Cardiac Amyloidosis
NCT05379101
Recruiting
The primary objective of this study is to define the intracardiac flow imaging biomarkers in cardiac amyloidosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/10/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Amyloidosis Cardiac, Healthy Adults
Register for Updates
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT05382338
Recruiting
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effect... Read More
Gender:
ALL
Ages:
Between 4 years and 21 years
Trial Updated:
07/10/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +80 locations
Conditions: Childhood Medulloblastoma
Register for Updates
Focused Intensive Repeated Stepping During Inpatient Rehabilitation Poststroke - A Quality Improvement Project
NCT05393661
Recruiting
The purpose of this quality improvement project was first to monitor usual physical therapy care (types \& cardiovascular intensity of interventions and amount of stepping practice provided) and outcomes. Following which educational training and support was provided to treating physical therapists to encourage implementation of evidence-based practices. Specifically, therapists were encouraged to prioritize the practice of walking, particularly at higher cardiovascular intensities during schedul... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/10/2025
Locations: Rehabilitation Hospital of Indiana, Indianapolis, Indiana
Conditions: Stroke, Acute, Gait, Hemiplegic
Register for Updates
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
NCT05413304
Recruiting
Background: Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults. Most people with these tumors survive less than 2 years. Researchers want to see if an anticancer drug (abemaciclib) can help. Objective: To see if researchers can measure how much abemaciclib is in a person's brain tumor and brain fluid after they take the drug for a few days. Eligibility: People aged 18 to 39 with recurrent high-grade glioma or diffuse midline glioma. Design: Particip... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
07/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioma
Register for Updates